Product | MedDrive®
INFOGRAPHIC
Leveraging the collective strength of Prime’s client membership to help control medical costs including biosimilars, medical rebates and low net cost savings.
Related news
Press releases
May 26, 2021
Prime Therapeutics launches MedDrive™, a first-of-its kind medical drug management program uniquely aligned with its Blue Plan clients
MedDrive to tackle the toughest challenges facing growing medical Rx drug spend, harness the multi-billion-dollar potential savings in biosimilar market
Press releases
November 3, 2021
Prime Therapeutics backs first interchangeable insulin biosimilar Semglee®
Formularies to include biosimilar over brand Lantus®, saving millions of dollars for health plans and their members
Stories
September 8, 2021
Prime leaders appear on PCMA’s podcast on topic “Understanding the value of biosimilars”
Prime’s Dr. Joseph Leach and Jarrod Henshaw discuss the opportunity, how the company’s new MedDrive™ medical drug management product will help manage growing specialty spend